The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

The success and pathogenicity of HIV-1 largely resides in the function of the viral protein Nef. Here, the authors propose that Nef modulates a T cell's ability to form an immunological synapse ...

Because most participating couples were cohabiting, the HIV-1 uninfected partners comprised an excellent control group for determining mortality attributable to HIV-1 infection, while accounting ...

COVID paused prevention efforts, which helped fuel the rise in new infections. Now federal funding cuts threaten to disrupt ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

U.S. withdrawal of $4 billion in AIDS funding risks over 4 million deaths and 6 million new HIV infections by 2029 ...